Matt cofounder Notable Labs in 2014. Currently his responsibilities include leading the overall vision and strategy, partnerships, recruiting, and any other company-related matters. Previously he was as a portfolio manager and trader at Clarium Capital, a global macro hedge fund. Matt started his career on a foreign exchange and interest rate sales and trading desk at Bank of America Merrill Lynch. Matt received his BA magna cum laude in Applied Economics and Management from Cornell University where he captained the cross country team and ran the 1,500 and 5,000 meter distance for the Big Red track team.
Designing Clinical Trials For Patients Not Drugs
Randomized controlled clinical trials have changed little since their inception. Bayesian statistical methods, technologies that stratify patients, and initial success in breast cancer should make adaptive trials more common. This talk will cover how adaptive trials benefit patients by making it more likely they receive an effective drug and benefit drug companies by reducing approval time and cost.
Precision medicine has incredible promise for patients. Enormous amounts of money and time are invested in developing technologies and targeted therapies. Genomics, proteomics, phosphorylation assays, RNA expression, organoid growth, and testing, and even delicate mass measurement of liquid cancer cells are explored. This innovation must be focused to maximize the benefit to the most important participants in our healthcare system, the patient. This track is about putting patient needs first, and understanding and accessing the latest (cancer) treatment options.